Vascular Biology · Nov 17, 2026

Temporal Trends and Disparities in Acute Myocardial Infarction Mortality Among Patients with Lipoprotein Metabolism Disorders: A Nationwide CDC-WONDER Analysis (1999–2020)

By Mustafa N, Iqbal J, Arshad A et al.

Background: Lipoprotein metabolism disorders (LMDs) contribute to residual cardiovascular risk following acute myocardial infarction (AMI), yet population-level mortality trends remain poorly defined. Objective: To evaluate AMI-related mortality trends among U.S. adults with LMDs from 1999–2020. Methods: A retrospective analysis of CDC WONDER data identified decedents aged ≥25 years with LMDs (ICD-10: E78) contributing to AMI (I21) as underlying cause. Age-adjusted mortality rates (AAMR) per 100,000 were analyzed using joinpoint regression, stratified by demographics. Results: Among 95,222 deaths, overall AAMR rose from 3.27 (1999) to 4.91 (2020). Three phases emerged: increase (1999–2004; APC: 6.19), stability (2004–2018; APC: -0.39), and resurgence (2018–2020; APC: 6.82). Men had higher AAMR than women (2.88 vs. 1.31). Non-Hispanic Whites (2.1) and Blacks (2.04) showed highest rates; Asians/Pacific Islanders lowest (1.39). Older adults (65–85+ years) bore greatest burden (AAMR: 9.69). Geographically, Midwest (2.33) and West (2.22) exceeded South (1.88) and Northeast (1.77). Non-metropolitan areas had markedly higher AAMR than metropolitan areas (9.08 vs. 2.37). Most deaths occurred in medical facilities (54.65%) versus home (36.71%). Conclusion: AMI-related mortality among U.S. adults with LMDs increased over two decades, with a concerning resurgence from 2018–2020 coinciding with the COVID-19 pandemic. Persistent disparities by sex, race, age, geography, and urbanization highlight urgent needs for targeted lipid management and equitable healthcare access to reduce cardiovascular mortality in this high-risk population.

doi.org/10.1530/vb-25-0005Populations

AgingResearch.News